Publication:
Phenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitors

dc.contributor.authorGonzález-Cofrade, Laura
dc.contributor.authorGreen, Jack P
dc.contributor.authorCuadrado, Irene
dc.contributor.authorAmesty, Ángel
dc.contributor.authorOramas-Royo, Sandra
dc.contributor.authorBrough, David
dc.contributor.authorEstévez-Braun, Ana
dc.contributor.authorHortelano, Sonsoles
dc.contributor.authorde Las Heras, Beatriz
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)es_ES
dc.contributor.funderAgencia Canaria de Investigación, Innovación y Sociedad de la Informaciónes_ES
dc.contributor.funderMinisterio de Universidades (España)es_ES
dc.date.accessioned2024-01-25T19:54:47Z
dc.date.available2024-01-25T19:54:47Z
dc.date.issued2023-03
dc.description.abstractDysregulated inflammasome activity, particularly of the NLRP3 inflammasome, is associated with the development of several inflammatory diseases. The study of molecules directly targeting NLRP3 is an emerging field in the discovery of new therapeutic compounds for the treatment of inflammatory disorders. Friedelane triterpenes are biologically active phytochemicals having a wide range of activities including anti-inflammatory effects. In this work, we evaluated the potential anti-inflammatory activity of phenolic and quinonemethide nor-triterpenes (1-11) isolated from Maytenus retusa and some semisynthetic derivatives (12-16) through inhibition of the NLRP3 inflammasome in macrophages. Among them, we found that triterpenes 6 and 14 were the most potent, showing markedly reduced caspase-1 activity, IL-1β secretion (IC50 = 1.15 µM and 0.19 µM, respectively), and pyroptosis (IC50 = 2.21 µM and 0.13 µM, respectively). Further characterization confirmed their selective inhibition of NLRP3 inflammasome in both canonical and non-canonical activation pathways with no effects on AIM2 or NLRC4 inflammasome activation.es_ES
dc.description.peerreviewedNoes_ES
dc.description.sponsorshipThis study was supported by Instituto de Salud Carlos III (PI17CIII/00012, PI20CIII/00018); Spanish Ministry of Science, Innovation and Universities (RTI2018-094356-B-C21) and Agencia Canaria de Investigación, Innovación y Sociedad de la Información (Pro ID 2021010037). LGC received a predoctoral fellowship award and a complementary mobility grant from the Spanish Ministry of Universities (FPU17/03519, EST22/00224). AA and SOR thanks to Cabildo de Tenerife (Agustín de Bethancourt Program).es_ES
dc.format.page106362es_ES
dc.format.volume132es_ES
dc.identifier.citationBioorg Chem. 2023 Mar:132:106362.es_ES
dc.identifier.doi10.1016/j.bioorg.2023.106362es_ES
dc.identifier.e-issn1090-2120es_ES
dc.identifier.journalBioorganic chemistryes_ES
dc.identifier.pubmedID36657273es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17376
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RTI2018-094356-B-C21es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FPU17/03519es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/EST22/00224es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI17-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2017)/PI17CIII/00012es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00018es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.bioorg.2023.106362es_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectNor-friedelane triterpeneses_ES
dc.subjectMaytenus retusaes_ES
dc.subjectNLRP3 inflammasomees_ES
dc.subjectASCes_ES
dc.subjectPyroptosises_ES
dc.subjectIL-1βes_ES
dc.subjectMacrophageses_ES
dc.subject.meshInflammasomeses_ES
dc.subject.meshTriterpeneses_ES
dc.subject.meshNLR Family, Pyrin Domain-Containing 3 Proteines_ES
dc.subject.meshPhenolses_ES
dc.subject.meshAnti-Inflammatory Agentses_ES
dc.titlePhenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitorses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione8434c4f-9d6e-418c-ba38-a3728163d52b
relation.isAuthorOfPublication.latestForDiscoverye8434c4f-9d6e-418c-ba38-a3728163d52b

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PhenolicQuinoneMethideNor-triterpenes_2023.pdf
Size:
2.32 MB
Format:
Adobe Portable Document Format
Description: